-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Mitigating and Managing Infection Risk in Adults Treated with CAR T-Cell Therapy

Program: Education Program
Session: Adult CAR-T Outcomes: Beyond the Acronyms (OS, PFS, CRS, ICANS)
Hematology Disease Topics & Pathways:
Research, Clinical Research, Real-world evidence, Treatment Considerations, Registries, Adverse Events
Monday, December 9, 2024, 4:30 PM-5:45 PM

Tania Jain, MD

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

Disclosures: Jain: Bristol Myers Squibb, Incyte, Abbvie, CTI, Kite, Cogent Biosciences, Blueprint Medicine, Telios pharma, Protagonist therapeutics, Galapagos, Tscan therapeutics, Karyopharm, Morphosys: Membership on an entity's Board of Directors or advisory committees; CTI Biopharma, Kartos therapeutics, Incyte, Bristol Myers Squibb: Research Funding.

See more of: Adult CAR-T Outcomes: Beyond the Acronyms (OS, PFS, CRS, ICANS)
See more of: Education Program
<< Previous Presentation | Next Presentation